No takes yet. Share an insight, caveat, or question.
Prospective cohort study reports high efficacy and safety of upadacitinib in Chinese patients with inflammatory bowel disease, suggesting its therapeutic potential.
Yao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: